[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615523":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":37,"locations":42,"responsibleParty":62,"collaborators":25,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":25,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Ohio State University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","permissive blood sugar control (70-140 mg\u002FdL)",[13,14],"Drug: Insulin","Device: DEXCOM Continuous Glucose Monitor",{"label":16,"type":6,"description":17,"interventionNames":18},"Standard of care","strict blood sugar control (70-110 mg\u002FdL)",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Insulin","Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg\u002FdL) or strict (70-110 mg\u002FdL). Participants and clinicians will be unblinded. Once randomized, an order set will be entered into the EMR that will alert pharmacy and nursing colleagues to the appropriate intrapartum glycemic control protocol.",[9,16],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"DEVICE","DEXCOM Continuous Glucose Monitor","Patients will be asked to wear an optional Continuous Glucose Monitor (CGM) to utilize during labor for research purposes. The CGM will be removed prior to hospital discharge and data will be extracted by trained research personnel. All participants already utilize a CGM device as part of standard of care as part of Hybrid Closed Loop (HCL) therapy. No clinical decisions will be made based upon data from the research CGM device. This data will not be extracted until after hospital discharge.",[9,16],[32,35],{"name":33,"affiliation":5,"role":34},"Anna Brewton, MD","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":5,"role":34},"Kartik K Venkatesh, MD, PhD",[38],{"name":33,"role":39,"phone":40,"phoneExt":25,"email":41},"CONTACT","614-293-8045","Anna.Brewton@osumc.edu",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"The Ohio State University Wexner Medical Center OB\u002FGYN Maternal and Fetal Medicine","RECRUITING","Columbus","Ohio","43210","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-82.99879,39.96118,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":60,"phoneExt":25,"email":61},"Kartik Venkatesh, MD, PhD","614-293-4780","kartik.venkatesh@osumc.edu",{"type":34,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Kartik K Venkatesh","Principal Investigator","100615523","phase-4-permissive-versus-strict-intrapartum-glucose-management-in-type-1-diabetes-prism-t1d-100615523",false,"NCT07293715","Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)","PRISM-T1D","Inclusion Criteria\n\n* Pregnant individuals\n* ≥ 18 years old\n* Type 1 diabetes\n* Intention for vaginal delivery and admitted to Labor and Delivery\n* Singleton, non-anomalous fetus\n* Gestational age greater than or equal to 35 weeks gestation.\n* Cervical dilation is less than 6 cm.\n* Delivering at the study institution\n\nExclusion criteria:\n\n* Scheduled cesarean delivery\n* Cervical dilation ≥ 6 cm on presentation to L\\&D\n* Receipt of antenatal corticosteroids within 7 days of randomization\n* Fetal demise\n* Major fetal anomaly (attached)\n* Multiple gestation\n* Non-English speaking","FEMALE","18 Years",{"count":75,"type":76},44,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","PRISM-TID is a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with type 1 diabetes (T1D) using hybrid closed loop therapy (HCL) who are admitted for labor management. Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg\u002FdL) or strict (70-110 mg\u002FdL). The primary aim of this trial it to demonstrate that permissive intrapartum glucose management is not associated with an increased risk of neonatal dysglycemia compared with strict intrapartum glucose management.",[82,83],"Pregnancy, High Risk","Type 1 Diabetes",[85,86,83,87,88,89],"Pregnancy","Continuous Glucose Monitor","Automated insulin delivery","Hybrid closed loop","Insulin pump","2026-04-28",{"date":92,"type":93},"2026-04-29","ACTUAL",{"date":95,"type":93},"2026-02-25",{"date":97,"type":76},"2027-06",{"name":5,"class":6},1]